Research programme : anti-Ras antibody therapeutics - Ajou University/Orum Therapeutics

Drug Profile

Research programme : anti-Ras antibody therapeutics - Ajou University/Orum Therapeutics

Alternative Names: RT 11i

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ajou University School of Medicine; Orum Therapeutics
  • Developer Ajou University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 May 2017 Research programme : anti-Ras antibody therapeutics - Ajou University/Orum Therapeutics is available for licensing as of 10 May 2017. http://www.orumrx.com/
  • 10 May 2017 Preclinical trials in Cancer in South Korea (Parenteral)
  • 10 May 2017 Pharmacodynamics data from a preclinical trial in Cancer released by Orum Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top